We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
29 Aug 2020 - 02 Sep 2020
Virtual Venue

Automated Technology Monitors Key Blood Analytes

By HospiMedica International staff writers
Posted on 24 Jan 2017
Print article
Image: The OptiScanner 5000 automated bedside monitoring system (Photo courtesy of OptiScan Biomedical).
Image: The OptiScanner 5000 automated bedside monitoring system (Photo courtesy of OptiScan Biomedical).
A novel device combines near-continuous glucose monitoring (CGM) with automatic serial monitoring of lactate levels, using the same micro-sample of the patient's blood.

The OptiScanner 6000 is an automated bedside monitoring system designed to overcome the limitations of manual monitoring of both glucose and lactate levels in intensive care unit (ICU) patients by serially measuring analytes in plasma, as opposed to whole blood. The system also measures lactate levels in order to optimize patient care in the ICU, as elevated lactate levels are common in patients with critical illnesses such as sepsis, burns, and trauma. Automated measurements are taken every 15 minutes using 0.13mL of plasma, providing trending capabilities and freeing nurses to perform direct patient care.

The automated process also eliminates handling errors associated with samples drawn by intermittent, manually operated technologies. The range of features include a touch screen; a graphic user interface (GUI) that virtually eliminates the need for in-service to assist in set up or operation; and reagent-free measurements, which removes the need for daily calibration. The OptiScanner 6000 is based on the OptiScanner 5000, both products of OptiScan Biomedical, and has received the European Union CE mark of approval.

“While near continuous monitoring of glucose in the ICU is critical, there are a number of additional metabolic analytes, including lactate, whose serial measurement is also important for optimizing patient care,” said Peter Rule, chairman and CEO of OptiScan Biomedical. “By providing ICU physicians the means to serially monitor both lactate and glucose in the same, single micro-sample of the patient's blood, we believe that the OptiScanner 6000 will play an important role in continuing to elevate the level of care delivered to ICU patients.”

It is estimated that approximately 20% of ICU patients have pre-existing diabetes and an additional 40-70% of ICU patients suffer from stress hyperglycemia, a temporary elevation of glucose levels, with all of these patients requiring accurate glucose monitoring to maintain tight glycemic control.


Print article

Channels

Business

view channel
Illustration

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.